Consistently, Khojandi et al. revealed that HO-1 endowed tumors with the ability to resist immune-mediated apoptosis, and combined treatment with HO-1 inhibition and anti-PD1 significantly decreased tumor volume in a mouse model of breast cancer and melanoma [147]. This evidence concerns the gene HMOX1 and breast carcinoma.